Mirador Therapeutics
Dirk Zajonc is an experienced professional in protein engineering and immunology. Currently serving as Executive Director of Protein Engineering at Mirador Therapeutics since April 2024, Dirk previously held the position of Head of Antibody Engineering at Protillion Biosciences. At Pfizer, Dirk managed a team focused on early-stage discovery projects in immune-oncology, specializing in antibody discovery and protein engineering. As a former Associate Professor at the La Jolla Institute for Allergy and Immunology, Dirk made significant contributions in the structural immunology of immune system proteins, particularly in the characterization of antigen recognition. Dirk also has a background in academia as a guest professor at Ghent University, a postdoctoral fellow at The Scripps Research Institute, and a graduate student at Friedrich Alexander University Erlangen-Nürnberg, where a Ph.D. was earned in Biology.
This person is not in any offices
Mirador Therapeutics
Mirador is a next-generation precision medicine company focused on immunology and inflammation. The company’s Mirador360 TM precision development engine leverages the latest advances in human genetics and cutting-edge data science to rapidly advance new precision medicines for patients living with chronic immune-mediated inflammatory and fibrotic diseases. Launched in 2024, Mirador has raised over $400 million from leading life sciences investors and is based in San Diego, CA.